  | GUREGHIAN, V., HERBST, H., KOZAR, I., MIHAJLOVIC, K., Malod-Dognin, N., Ceddia, G., ANGELI, C., WURTH-MARGUE, C., RANDIC, T., PHILIPPIDOU, D., TETSI NOMIGNI, M., HEMEDAN, A., TRANCHEVENT, L.-C., LONGWORTH, J., Bauer, M., BADKAS, A., GAIGNEAUX, A., Muller, A., OSTASZEWSKI, M., ... KREIS, S. (October 2023). A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Therapy, 30 (10), 1330 - 1345. doi:10.1038/s41417-023-00640-z  Peer Reviewed verified by ORBi |
 | RANDIC, T., MAGNI, S., PHILIPPIDOU, D., Margue, C., GRZYB, K., PREIS, J. R., WROBLEWSKA, J. P., NAZAROV, P., MITTELBRONN, M., FRAUENKNECHT, K., SKUPIN, A., & KREIS, S. (25 July 2023). Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. Cell Reports, 42 (7), 112696. doi:10.1016/j.celrep.2023.112696 Peer Reviewed verified by ORBi |
 | RANDIC, T., KOZAR, I., MARGUE, C., Utikal, J., & KREIS, S. (29 May 2021). NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 99. doi:10.1016/j.ctrv.2021.102238 Peer Reviewed verified by ORBi |